摘要
目的:研究替吉奥+顺铂与吉西他滨+顺铂对EGFR野生型晚期NSCLC患者血清及肿瘤组织中恶性指标的影响。方法:回顾下分析58例EGFR野生型的晚期非小细胞肺癌患者的病历资料,将接受替吉奥+顺铂化疗的患者纳入实验组、将接受吉西他滨+顺铂化疗的患者纳入对照组,测定血清中肿瘤标志分子的含量以及肿瘤组织中原癌基因、抑癌基因的表达量。结果:治疗后,实验组血清中肿瘤标志物CEA、NSE、Cyfra21-1、PCDGF、VEGF、TK1的含量显著低于对照组;实验组肿瘤组织中Pim-1、LUNX、PFKFB3、PFKFB4、Ki67的含量显著低于对照组,TCF21、PDCD5、ASPP1、ASPP2、p53、EFEMP1的含量显著高于对照组。结论:替吉奥+顺铂治疗EGFR野生型晚期NSCLC的疗效优于吉西他滨+顺铂,能够更为有效的杀伤癌细胞、调节原癌基因和抑癌基因的表达。
Objective：To study the effects of S-1 ＋ cisplatin and gemcitabine ＋ cisplatin on malignant indexes of ser-um and tumor tissue in advanced NSCLC patients with wild-type EGFR.Methods：The medical records of 58 cases of advanced non-small cell lung cancer patients with wild-type EGFR were retrospectively analyzed,patients who received S-1 ＋ cisplatin chemotherapy were included in the experimental group,patients who received gemcitabine ＋ cisplatin chemotherapy were in-cluded in the control group,and then the levels of tumor markers in serum and the expression levels of proto-oncogenes and tumor suppressor genes in tumor tissue were determined.Results：After treatment,serum tumor markers CEA,NSE,Cy-fra21-1,PCDGF,VEGF and TK1 levels of experimental group were significantly lower than those of control group;Pim-1, LUNX,PFKFB3,PFKFB4 and Ki67 levels in tumor tissue of experimental group were significantly lower than those of control group,and TCF21,PDCD5,ASPP1,ASPP2,p53 and EFEMP1 levels were significantly higher than those of control group. Conclusion：S-1 ＋ cisplatin has better curative effect on advanced NSCLC with wild-type EGFR than gemcitabine ＋ cisplatin, and can more effectively kill cancer cells and regulate the expression of proto-oncogenes and tumor suppressor genes.
出处
《海南医学院学报》
CAS
2016年第15期1710-1713,共4页
Journal of Hainan Medical University
基金
陕西省自然科学基础研究计划项目(2012JM4017)~~
关键词
非小细胞肺癌
表皮生长因子受体
肿瘤标志物
原癌基因
抑癌基因
Non-small cell lung cancer
Epidermal growth factor receptor
Tumor marker
Proto-oncogene
Tumor suppresser gene
